Our data indicate that Notch receptor-targeting antibodies or small-molecule γ-secretase inhibitors do not induce significant liver vascular pathology and should be as effective as anti- Dll4 treatment at dysregulating tumor-related or ischemia-related angiogenesis, which can be beneficial in some therapeutic settings. This evidence concerns the gene DLL4 and neoplasm.